In view of both metabolic and cardiac side effects associated with long-term antipsychotics use, these CB1R antagonists, together with some first-generation CB1R antagonists (i.e., AM 251 and AM 281), might thus confer dual actions in clinical practice: one to protect against AP drug-induced cardiotoxicity (as evidenced by the present study), and the other to improve AP drug-induced metabolic disorders in longer-term medication. The gene discussed is CNR1; the disease is metabolic disease.